The anti-obesity effect of the palatinose-based formula inslow is likely due to an increase in the hepatic PPAR-α and adipocyte PPAR-γ gene expressions

Journal of Clinical Biochemistry and Nutrition

Volumn 40, Issue 3, 2007, Pages 234-241

  Matsuo, Kaoru ^a   Arai, Hidekazu ^a   Muto, Kazusa ^a   Fukaya, Makiko ^a   Sato, Tadatoshi ^a   Mizuno, Akira ^a   Sakuma, Masae ^a   Yamanaka Okumura, Hisami ^a   Sasaki, Hajime ^b   Yamamoto, Hironori ^a   Taketani, Yutaka ^a   Doi, Toshio ^a   Takeda, Eiji ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b MEIJI DAIRIES CORPORATION   (Japan)

Author keywords

Fat oxidation; Insulin sparing effect; Palatinose; PPAR ; PPAR

Indexed keywords

ADIPONECTIN; GLUCOSE; INSLOW; INSULIN; MESSENGER RNA; PALATINOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 2;

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFECT; DRUG MECHANISM; EPIDIDYMIS FAT; FATTY ACID OXIDATION; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; INTRAABDOMINAL FAT; LIPID METABOLISM; LIPID STORAGE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PANCREAS ISLET; POSTPRANDIAL STATE; RAT; TRIACYLGLYCEROL BLOOD LEVEL;

RATTUS;

EID: 34250860120     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.40.234     Document Type: Article

References (38)

1. Ford, E.S., Giles, W.H., and Dietz, W.H.: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 287, 356-359, 2002.
2. Grundy, S.M., Brewer, H.B. Jr., Cleeman, J.I., Smith, S.C. Jr., and Lenfant, C.: American heart association; national heart, lung, and blood institute, definition of metabolic syndrome: report of the national heart, lung, and blood institute/ American heart association conference on scientific issues related to definition. Circulation, 109, 433-438, 2004.
3. Lebovitz, H.E.: The relationship of obesity to the metabolic syndrome. Int. J. Clin. Pract. Suppl., 134, 18-27, 2003.
4. Lubrano, C., Cornoldi, A., Pili, M., Falcone, S., Brandetti, F., Fabbrini, E., Ginanni-Corradini, S., Eramo, A., Marini, M., Migliaccio, S., Giancotti, V., Badiali, M., Falsetto, N., Prossomariti, G., and Spera, G.: Reduction of risk factors for cardiovascular diseases in morbid-obese patients following biliary-intestinal bypass: 3 years' follow-up. Int. J. Obes. Relat. Metab. Disord., 28, 1600-1606, 2004.
5. Lee, C.H., Olson, P., and Evans, R.M.: Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors. Endocrinology, 44, 2201-2207, 2003.
6. Dreyer, C., Keller, H., Mahfoudi, A., Laudet, V., Krey, G., and Wahli, W.: Positive regulation of the peroxisomal β-oxidation pathway by fatty acids through activation of peroxisome proliferator-activated receptors (PPAR). Biol. Cell, 77, 67-76, 1993.
7. Peters, J.M., Hennuyer, N., Staels, B., Fruchart, J.C., Fievet, C., Gonzalez, F.J., and Auwerx, J.: Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor - deficient mice. J. Biol. Chem., 272, 27307-27312, 1997.
8. Barak, Y., Nelson, M.C., Ong, E.S., Jones, Y.Z., Ruiz-Lozano, P., Chien, K.R., Koder, A., and Evans, R.M.: PPAR is required for placental, cardiac, and adipose tissue development. Mol Cell, 4, 585-595, 1999.
9. Kubota, N., Terauchi, Y., Miki, H., Tamemoto, H., Yamauchi, T., Komeda, K., Satoh, S., Nakano, R., Ishii, C., Sugiyama, T., Eto, K., Tsubamoto, Y., Okuno, A., Murakami, K., Sekihara, H., Hasegawa, G., Naito, M., Toyoshima, Y., Tanaka, S., Shiota, K., Kitamura, T., Fujita, T., Ezaki, O., Aizawa, S., and Kadowaki, T.: PPAR mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell, 4, 597-609, 1999.
10. Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C., Reitman, M.L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., and Kadowaki, T.: The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med., 7, 941-946, 2001.
11. Kadowaki, T. and Yamauchi, T.: Adiponectin and adiponectin receptors. Endocr. Rev., 26, 439-451, 2005.
12. Doebber, T.W., Kelly, L.J., Zhou, G., Meurer, R., Biswas, C., Li, Y., Wu, M.S., Ippolito, M.C., Chao, Y.S., Wang, P.R., Wright, S.D., Moller, D.E., and Berger, J.P.: MK-0767, a novel dual PPARalpha/gamma agonist, displays robust anti-hyperglycemic and hypolipidemic activities. Biochem. Biophys. Res. Commun., 318, 323-328, 2004.
13. Guo, Q., Sahoo, S.P., Wang, P.R., Milot, D.P., Ippolito, M.C., Wu, M.S., Baffic, J., Biswas, C., Hernandez, M., Lam, M.H., Sharma, N., Han, W., Kelly, L.J., MacNaul, K.L., Zhou, G., Desai, R., Heck, J.V., Doebber, T.W., Berger, J.P., Moller, D.E., Sparrow, C.P., Chao, Y.S., and Wright, S.D.: A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology, 145, 1640-1648, 2004.
14. Reifel-Miller, A., Otto, K., Hawkins, E., Barr, R., Bensch, W.R., Bull, C., Dana, S., Klausing, K., Martin, J.A., Rafaeloff-Phail, R., Rafizadeh-Montrose, C., Rhodes, G., Robey, R., Rojo, I., Rungta, D., Snyder, D., Wilbur, K., Zhang, T., Zink, R., Warshawsky, A., and Brozinick, J.T.: A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia. Mol. Endocrinol., 19, 1593-1605, 2005.
15. Jenkins, D.J., Wolever, T.M., Taylor, R.H., Barker, H., Fielden, H., Baldwin, J.M., Bowling, A.C., Newman, H.C., Jenkins, A.L., and Goff, D.V.: Glycemic index of foods: a physiological basis for carbohydrate exchange. Am. J. Clin. Nutr., 34, 362-366, 1981.
16. Schulze, M.B., Liu, S., Rimm, E.B., Manson, J.E., Willett, W.C., and Hu, F.B.: Glycemic index, glycemic load, and dietary fiber intake and incidence of type 2 diabetes in younger and middle-aged women. Am. J. Clin. Nutr., 80, 348-356, 2004.
17. Liljeberg, H. and Bjorck, I.: Effects of a low-glycaemic index spaghetti meal on glucose tolerance and lipaemia at a subsequent meal in healthy subjects. Eur. J. Clin. Nutr., 54, 24-28, 2000.
18. Pawlak, D.B., Kushner, J.A., and Ludwig, D.S.: Effects of dietary glycaemic index on adiposity, glucose homoeostasis, and plasma lipids in animals. Lancet, 364, 778-785, 2004.
19. Arai, H., Mizuno, A., Matsuo, K., Fukaya, M., Sasaki, H., Arima, H., Matsuura, M., Taketani, Y., Doi, T., and Takeda, E.: Effect of a novel palatinose-based liquid balanced formula (Inslow) on glucose and lipid metabolism in male Sprague-Dawley rats after short- and long-term ingestion. Metabolism, 53, 977-983, 2004.
20. Folch, J., Lees, M.S., and Stanley, G.H.: A simple method for the isolation and purification of total lipids from animal tissues. J. Biol. Chem., 116, 497-509, 1957.
21. Maedler, K., Oberholzer, J., Bucher, P., Spinas, G.A., and Donath, M.Y.: Monounsaturated fatty acids prevent the deleterious effects of palmitate and high glucose on human pancreatic β-cell turnover and function. Diabetes, 52, 726-733, 2003.
22. 2+ concentration. J. Biol. Chem., 273, 33501-33507, 1998.
23. Song, S.H., Rhodes, C.J., Veldhuis, J.D., and Butler, P.C.: Diazoxide attenuates glucose-induced defects in first-phase insulin release and pulsatile insulin secretion in human islets. Endocrinology, 144, 3399-3405, 2003.
24. Ferre, P.: The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes, 53, 43S-50S, 2004.
25. Lee, S.S., Pineau, T., Drago, J., Lee, E.J., Owens, J.W., Kroetz, D.L., Fernandez-Salguero, P.M., Westphal, H., and Gonzalez, F.J.: Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol. Cell. Biol., 15, 3012-3022, 1995.
26. Aoyama, T., Peters, J.M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T., and Gonzalez, F.J.: Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPA-Ralpha). J. Biol. Chem., 273, 5678-5684, 1998.
27. Fleury, C., Neverova, M., Collins, S., Raimbault, S., Champigny, O., Levi-Meyrueis, C., Bouillaud, F., Seldin, M.F., Surwit, R.S., Ricquier, D., and Warden, C.H.: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat. Genet., 15, 269-272, 1997.
28. Chavin, K.D., Yang, S., Lin, H.Z., Chatham, J., Chacko, V.P., Hoek, J.B., Walajtys-Rode, E., Rashid, A., Chen, C.H., Huang, C.C., Wu, T.C., Lane, M.D., and Diehl, A.M.: Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J. Biol. Chem., 274, 5692-5700, 1999.
29. Cortez-Pinto, H., Lin, H.Z., Yang, S.Q., Da Costa, S.O., and Diehl, A.M.: Lipids up-regulate uncoupling protein 2 expression in rat hepatocytes. Gastroenterology, 116, 1184-1193, 1999.
30. Shiota, G. and Tsuchiya, H.: Pathophysiology of NASH: Insulin Resistance, Free Fatty Acids and Oxidative Stress. J. Clin. Biochem. Nutr., 38, 127-132, 2006.
31. Innoe, I., Noji, S., Shen, M.Z., Takahashi, K., and Katayama, S.: The peroxisome proliferator-activated receptor (PPAR) regulates the plasma thiobarbituric acid-reactive substance (TBARS) level. Biochem. Biophys. Res. Commun., 237, 606-610, 1997.
32. Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Conn, J.S., Ramakrishnan, R., and Ginsberg, H.N.: Effects of the PPAR gamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J. Clin. Invest., 115, 1323-1332, 2005.
33. Ide, T.: Seeking for the endogenous ligands for PPARγ. J. Clin. Biochem. Nutr., 37, 39-44, 2005.
34. Okuno, A., Tamemoto, H., Tobe, K., Ueki, K., Mori, Y., Iwamoto, K., Umesono, K., Akanuma, Y., Fujiwara, T., Horikoshi, H., Yazaki, Y., and Kadowaki, T.: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest., 101, 1354-1361, 1998.
35. Yamauchi, T., Kamon, J., Waki, H., Murakami, K., Motojima, K., Komeda, K., Ide, T., Kubota, N., Terauchi, Y., Tobe, K., Miki, H., Tsuchida, A., Akanuma, Y., Nagai, R., Kimura, S., and Kadowaki, T.: The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPAR-gamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol Chem., 276, 41245-41254, 2001.
36. Hammarstedt, A., Sopasakis, V.R., Gogg, S., Jansson, P.A., and Smith, U.: Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia, 48, 96-104, 2005.
37. Fruebis, J., Tsao, T.S., Javorschi, S., Ebbets-Reed, D., Erickson, M.R., Yen, F.T., Bihain, B.E., and Lodish, H.F.: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc. Natl. Acad. Sci. U.S.A., 98, 2005-2010, 2001.
38. Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., Eto, K., Akanuma, Y., Froguel, P., Foufelle, F., Ferre, P., Carling, D., Kimura, S., Nagai, R., Kahn, B.B., and Kadowaki, T.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med., 8, 1288-1295, 2002.